KR20220133258A - 화합물 및 이의 용도 - Google Patents
화합물 및 이의 용도 Download PDFInfo
- Publication number
- KR20220133258A KR20220133258A KR1020227029525A KR20227029525A KR20220133258A KR 20220133258 A KR20220133258 A KR 20220133258A KR 1020227029525 A KR1020227029525 A KR 1020227029525A KR 20227029525 A KR20227029525 A KR 20227029525A KR 20220133258 A KR20220133258 A KR 20220133258A
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- compound
- subject
- cell
- brg1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062967359P | 2020-01-29 | 2020-01-29 | |
| US62/967,359 | 2020-01-29 | ||
| PCT/US2021/015876 WO2021155262A1 (en) | 2020-01-29 | 2021-01-29 | Compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220133258A true KR20220133258A (ko) | 2022-10-04 |
Family
ID=76970694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227029525A Pending KR20220133258A (ko) | 2020-01-29 | 2021-01-29 | 화합물 및 이의 용도 |
Country Status (17)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12282014B2 (en) | 2015-11-19 | 2025-04-22 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers |
| EP3746124A4 (en) | 2018-01-30 | 2021-10-27 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
| US12473334B2 (en) | 2018-10-17 | 2025-11-18 | Dana-Farber Cancer Institute, Inc. | SWI/SNF family chromatin remodeling complexes and uses thereof |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12509453B2 (en) | 2019-01-29 | 2025-12-30 | Foghorn Therapeutics Inc. | BRM/BRG1 inhibitors and uses thereof |
| EP3917517A4 (en) | 2019-01-29 | 2023-01-25 | Foghorn Therapeutics Inc. | CONNECTIONS AND USES THEREOF |
| WO2021155262A1 (en) | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021155264A1 (en) | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021236080A1 (en) * | 2020-05-20 | 2021-11-25 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| US12606553B2 (en) | 2021-03-09 | 2026-04-21 | Foghorn Therapeutics Inc. | Crystalline forms, compositions containing same, and methods of their use |
| WO2022198043A1 (en) * | 2021-03-19 | 2022-09-22 | Foghorn Therapeutics Inc. | Therapeutic regimens of an inhibitor of the enzymatic activity of brg1 and brm |
| US20240374605A1 (en) * | 2021-07-29 | 2024-11-14 | Foghorn Therapeutics Inc. | Methods of treating cancer |
| WO2023196560A1 (en) * | 2022-04-08 | 2023-10-12 | Foghorn Therapeutics Inc. | Methods of treating cancer |
| US20250339441A1 (en) * | 2022-04-08 | 2025-11-06 | Foghorn Therapeutics Inc. | Methods of treating cancer |
| AU2023270055A1 (en) * | 2022-05-11 | 2024-11-28 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2024125543A1 (zh) * | 2022-12-16 | 2024-06-20 | 苏州科睿思制药有限公司 | 达洛色替的晶型及其制备方法和用途 |
| WO2024249769A2 (en) * | 2023-06-02 | 2024-12-05 | Foghorn Therapeutics Inc. | Combination therapy for treating hematological cancers |
| IL326645A (en) * | 2023-08-21 | 2026-04-01 | Ideaya Biosciences Inc | Pharmaceutical compositions comprising a pkc inhibitor |
| WO2025080769A1 (en) * | 2023-10-10 | 2025-04-17 | Foghorn Therapeutics Inc. | Methods of treating cancer |
Family Cites Families (157)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2788341A (en) | 1953-03-06 | 1957-04-09 | Ciba Pharm Prod Inc | Process for the manufacture of aminoacyl compounds |
| US3624097A (en) | 1969-07-22 | 1971-11-30 | Warner Lambert Co | N-pyridine 5-aminooxazoles |
| US4109496A (en) | 1977-12-20 | 1978-08-29 | Norris Industries | Trapped key mechanism |
| FR2568880B1 (fr) | 1984-08-07 | 1986-12-12 | Synthelabo | Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique |
| US4868103A (en) | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| DE69210091T2 (de) | 1991-05-31 | 1996-10-02 | Sumitomo Pharma | Leukotrien-B4-Antagonisten |
| EP0552108B1 (en) | 1992-01-17 | 1999-11-10 | Lakowicz, Joseph R. | Energy transfer phase-modulation fluoro-immunoassay |
| JP3537141B2 (ja) | 1992-10-30 | 2004-06-14 | ザ ゼネラル ホスピタル コーポレーション | 新種蛋白質分離のための相互作用を用いる補捉システム |
| US5656465A (en) | 1994-05-04 | 1997-08-12 | Therion Biologics Corporation | Methods of in vivo gene delivery |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US5677158A (en) | 1995-06-07 | 1997-10-14 | Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| US5801030A (en) | 1995-09-01 | 1998-09-01 | Genvec, Inc. | Methods and vectors for site-specific recombination |
| US6180612B1 (en) | 1997-10-31 | 2001-01-30 | The University Of Virginia Patent Foundation | Methods and compositions for targeting DNA metabolic processes using aminoglycoside derivatives |
| US6683058B1 (en) | 1998-04-15 | 2004-01-27 | Regents Of The University Of California | Methods for therapy of neurodegenerative disease of the brain |
| CA2329259C (en) | 1998-05-27 | 2003-08-05 | Avigen, Inc. | Convection-enhanced delivery of aav vectors |
| JP2000095767A (ja) | 1998-09-28 | 2000-04-04 | Takeda Chem Ind Ltd | 性腺刺激ホルモン放出ホルモン拮抗剤 |
| WO2000024392A1 (en) | 1998-10-26 | 2000-05-04 | Sumitomo Pharmaceuticals Company, Limited | β-AMYLOID FORMATION INHIBITORS |
| DE60014339T8 (de) | 1999-04-02 | 2006-04-27 | Neurogen Corp., Branford | Aryl- und heteroaryl-kondensierte aminoalkyl-imidazol-derivate: selektive modulatoren der gabaa-rezeptoren |
| CA2369553A1 (en) | 1999-04-02 | 2000-10-12 | Raymond F. Horvath | N-benzimidazolylmethyl and n-indolylmethyl-benzamides and their use as crf modulators |
| US7205103B2 (en) | 2000-02-11 | 2007-04-17 | The Salk Institute For Biological Studies | Method of regulating transcription in a cell |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| HK1052372A1 (zh) | 2000-02-24 | 2003-09-11 | Xcyte Therapies, Inc. | 细胞的同步刺激和富集 |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| EP1301214A2 (en) | 2000-05-26 | 2003-04-16 | Chiron Corporation | Methods of transducing neural cells using lentivirus vectors |
| AU2001280576A1 (en) | 2000-07-18 | 2002-01-30 | Uab Research Foundation | Tissue-specific self-inactivating gene therapy vector |
| WO2002020737A2 (en) | 2000-09-07 | 2002-03-14 | Vanderbilt University | Genome engineering by cell-permeable dna site-specific recombinases |
| US6551786B2 (en) | 2001-01-04 | 2003-04-22 | Myriad Genetics, Inc. | Screen assay for selecting protein-protein interaction modulators |
| JP2003033179A (ja) | 2001-07-05 | 2003-02-04 | Asahi Kasei Corp | 可逆的遺伝子導入ベクター |
| JP2003077651A (ja) | 2001-08-30 | 2003-03-14 | Sharp Corp | 有機エレクトロルミネッセンス素子の製造方法 |
| EP1434579B1 (en) | 2001-10-09 | 2011-06-08 | Amgen Inc. | Imidazole derivatives as antiinflammatory agents |
| US20050079512A1 (en) | 2003-02-26 | 2005-04-14 | Emerson Beverly M. | Methods of modulating gene expression |
| WO2004078939A2 (en) | 2003-03-03 | 2004-09-16 | University Of Massachusetts | REGULATION OF Mdm2 FUNCTION |
| US20050130919A1 (en) | 2003-07-18 | 2005-06-16 | University Of Massachusetts | Regulatable promoters for synthesis of small hairpin RNA |
| AU2004283053A1 (en) | 2003-10-20 | 2005-05-06 | Nsgene A/S | In vivo gene therapy of Parkinson's Disease |
| WO2005085443A2 (en) | 2004-03-01 | 2005-09-15 | Massachusetts Institute Of Technology | Rnai-based therapeutics for allergic rhinitis and asthma |
| WO2005112620A2 (en) | 2004-05-18 | 2005-12-01 | Massachusetts Institute Of Technology | A cre-lox based method for conditional rna interference |
| AU2005261487A1 (en) | 2004-07-12 | 2006-01-19 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide derivatives as inhibitors of histone deacetylase |
| MX2007005611A (es) | 2004-11-11 | 2007-07-11 | Ferrer Int | Compuestos de imidazo[1,2-a]piridina, composiciones, usos y metodos relacionados. |
| WO2006070806A1 (ja) | 2004-12-28 | 2006-07-06 | Taiho Pharmaceutical Co., Ltd. | 新規ベンゾイミダゾール化合物及び該化合物を含有する医薬組成物 |
| US20070105181A1 (en) | 2005-05-04 | 2007-05-10 | Invitrogen Corporation | Identification of cancer biomarkers and phosphorylated pdroteins |
| BRPI0716583A2 (pt) | 2006-08-24 | 2013-10-01 | Australian Nuclear Science Tec | ligandos fluorados para marcar recptores de benzodiazepina perifÉricos |
| US8324367B2 (en) | 2006-11-03 | 2012-12-04 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
| PH12012502343A1 (en) | 2007-05-23 | 2013-06-17 | Siga Tech Inc | Antiviral drugs for treatment or prevention of dengue infection |
| WO2008157500A1 (en) | 2007-06-17 | 2008-12-24 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| CA2618163A1 (en) | 2008-02-07 | 2009-08-07 | K. W. Michael Siu | Head and neck cancer biomarkers |
| CA2716947A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imidazo [4,5-b] pyridine derivatives used as raf inhibitors |
| EP2349484A2 (en) | 2008-07-15 | 2011-08-03 | Novartis AG | Heteroaryl derivatives as dgat1 inhibitors |
| CA2751412A1 (en) | 2009-02-05 | 2010-08-12 | Targeted Delivery Technologies Limited | Methods of reducing the proliferation and viability of microbial agents |
| CN103038231B (zh) | 2010-03-17 | 2016-04-20 | 泰纬生命科技股份有限公司 | Hec1活性调节剂及其方法 |
| EP2561351B1 (en) | 2010-04-22 | 2015-12-09 | British Columbia Cancer Agency Branch | Novel biomarkers and targets for ovarian carcinoma |
| US20120035244A1 (en) | 2010-07-29 | 2012-02-09 | The Regents Of The University Of Michigan | Parp1 targeted therapy |
| US9072052B2 (en) | 2010-08-09 | 2015-06-30 | Blackberry Limited | Communication system providing context-based mobile wireless communications device power consumption management and related methods |
| US9656959B2 (en) | 2010-12-22 | 2017-05-23 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
| WO2012138789A2 (en) | 2011-04-04 | 2012-10-11 | Netherlands Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment |
| EP2697368B1 (en) | 2011-04-15 | 2019-06-05 | Genelux Corporation | Clonal strains of attenuated vaccinia viruses and methods of use thereof |
| US8945861B2 (en) | 2011-08-03 | 2015-02-03 | Pierce Biotechnology, Inc. | Methods for isotopically labeling biomolecules using mammalian cell-free extracts |
| US9403843B2 (en) | 2012-02-01 | 2016-08-02 | The Trustees Of Columbia University In The City Of New York | Cysteine protease inhibitors and uses thereof |
| EP2809660B1 (en) | 2012-02-02 | 2016-01-20 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating il-17 |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| CN105209621B (zh) | 2012-12-12 | 2021-05-25 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| KR102955556B1 (ko) | 2012-12-12 | 2026-04-22 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물 |
| US9410943B2 (en) | 2013-03-14 | 2016-08-09 | The Board Of Trustees Of The Leland Stanford Junior University | Methods, compositions and screens for therapeutics for the treatment of synovial sarcoma |
| ES2900301T3 (es) | 2013-03-15 | 2022-03-16 | Novartis Ag | Biomarcadores asociados con la inhibición de BRM |
| EP2968318A4 (en) | 2013-03-15 | 2016-12-14 | Shifa Biomedical Corp | ANTI-PCSK9 COMPOUNDS AND METHODS FOR TREATING AND / OR PREVENTING CARDIOVASCULAR DISEASES |
| US10976320B2 (en) | 2013-05-21 | 2021-04-13 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for identifying and treating cancer patients |
| JP6411342B2 (ja) | 2013-07-03 | 2018-10-24 | 武田薬品工業株式会社 | アミド化合物 |
| US20160130663A1 (en) | 2013-07-12 | 2016-05-12 | National Cancer Center | Method for predicting response to cancer treatment |
| EP3022197B1 (en) | 2013-07-15 | 2017-09-06 | Boehringer Ingelheim International GmbH | Novel tetra- and pentasubstituted benzimidazolium compounds |
| WO2015046193A1 (ja) * | 2013-09-25 | 2015-04-02 | 塩野義製薬株式会社 | Trpv4阻害活性を有する芳香族複素環式アミン誘導体 |
| US10266515B2 (en) | 2013-12-30 | 2019-04-23 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| US9919998B2 (en) * | 2014-02-06 | 2018-03-20 | Rutgers, The State University Of New Jersey | Antibacterial agents: Nα-aroyl-N-aryl-phenylalaninamides |
| GB201402771D0 (en) | 2014-02-17 | 2014-04-02 | Isis Innovation | Biomarker & therapeutic target for sarcoma |
| EP3177640B1 (en) | 2014-08-08 | 2020-05-06 | The Board of Trustees of the Leland Stanford Junior University | High affinity pd-1 agents and methods of use |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9636323B2 (en) | 2014-10-27 | 2017-05-02 | Baylor College Of Medicine | Method of treating cancer that overexpresses TopBP1 |
| CN104530013B (zh) | 2014-12-04 | 2016-06-29 | 中国农业大学 | 基于吲哚环的吡唑酰胺类化合物作为农用杀菌剂的用途 |
| US9546296B2 (en) | 2014-12-15 | 2017-01-17 | Ppg Industries Ohio, Inc. | Coating compositions, coatings and methods for sound and vibration damping and water resistance |
| US9932340B2 (en) | 2014-12-18 | 2018-04-03 | Abbvie Inc. | Substituted indoles |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| MA41598A (fr) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| WO2016160718A1 (en) | 2015-03-27 | 2016-10-06 | University Of Washington | Methods for treatment of retinal disease by photoreceptor gene expression modulation |
| US20180140722A1 (en) | 2015-04-06 | 2018-05-24 | The University Of North Carolina At Chapel Hill | Methods and compositions for treatment of heart failure |
| EP3108883A1 (en) | 2015-06-22 | 2016-12-28 | Fundació Institut de Recerca Biomèdica de Bellvitge | Therapeutic uses of non-peptide inhibitors of the calcineurin - nfat signalling pathway |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| CA2994969A1 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| US20170100396A1 (en) | 2015-10-07 | 2017-04-13 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza |
| HUE067449T2 (hu) | 2015-10-15 | 2024-10-28 | Servier Lab | Ivozidenib, citarabin és daunorubicin vagy idarubicin kombinációs terápa akut mielogén leukémia kezelésére |
| US12282014B2 (en) | 2015-11-19 | 2025-04-22 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers |
| US12233060B2 (en) | 2016-01-08 | 2025-02-25 | The Institute Of Cancer Research: Royal Cancer Hospital | Inhibitors of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR) for use in methods of treating cancer |
| CA3015753A1 (en) | 2016-02-26 | 2017-08-31 | Celgene Corporation | Idh2 inhibitors for the treatment of haematological maligancies and solid tumours |
| WO2017150395A1 (ja) | 2016-02-29 | 2017-09-08 | フジテック株式会社 | 情報提供装置、エレベータの群管理システム、及びエレベータシステム |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| WO2018064589A1 (en) | 2016-09-29 | 2018-04-05 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation using a mutant e3 ubiquitin ligase |
| US10207998B2 (en) | 2016-09-29 | 2019-02-19 | Duke University | Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof |
| US12023385B2 (en) | 2017-02-08 | 2024-07-02 | Dana-Farber Cancer Institute, Inc. | Tunable endogenous protein degradation with heterobifunctional compounds |
| KR20190140438A (ko) * | 2017-02-28 | 2019-12-19 | 에피자임, 인코포레이티드 | 암 치료를 위한 smarca2의 저해 |
| EP3601326A4 (en) | 2017-03-20 | 2020-12-16 | The Broad Institute, Inc. | COMPOUNDS AND METHODS OF REGULATING INSULIN SECRETION |
| WO2019040098A1 (en) | 2017-08-21 | 2019-02-28 | Dana-Farber Cancer Institute, Inc. | METHODS OF MODULATING THE INTERACTION BETWEEN BAF COMPLEXES AND EWS-FLI1 |
| KR20200043433A (ko) | 2017-08-21 | 2020-04-27 | 메르크 파텐트 게엠베하 | 아데노신 수용체 길항제로서의 벤즈이미다졸 유도체 |
| CN111601799B (zh) | 2018-01-15 | 2023-06-09 | Ucb生物制药有限责任公司 | 作为Il-17调节剂的稠合咪唑衍生物 |
| EP3740482A1 (en) | 2018-01-17 | 2020-11-25 | Migal Galilee Research Institute Ltd. | New methionine metabolic pathway inhibitors |
| CN112236172A (zh) | 2018-01-30 | 2021-01-15 | 福宏治疗公司 | 用于治疗病症的方法和化合物 |
| EP3746124A4 (en) | 2018-01-30 | 2021-10-27 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
| WO2019226915A1 (en) | 2018-05-25 | 2019-11-28 | Rutgers, The State University Of New Jersey | Antibacterial agents: dual-targeted rna polymerase inhibitors |
| US20210260171A1 (en) | 2018-06-21 | 2021-08-26 | Foghorn Therapeutics Inc. | Methods of treating disorders |
| WO2019246430A1 (en) | 2018-06-21 | 2019-12-26 | Foghorn Therapeutics Inc. | Methods of treating disorders |
| CN112585136B (zh) | 2018-08-17 | 2024-06-25 | 诺华股份有限公司 | 作为smarca2/brm atp酶抑制剂的脲化合物和组合物 |
| US20210171958A1 (en) | 2018-08-23 | 2021-06-10 | Foghorn Therapeutics Inc. | Methods of treating cancer |
| WO2020081556A2 (en) | 2018-10-17 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Non-canonical swi/snf complex and uses thereof |
| US12473334B2 (en) | 2018-10-17 | 2025-11-18 | Dana-Farber Cancer Institute, Inc. | SWI/SNF family chromatin remodeling complexes and uses thereof |
| EP3883580A4 (en) | 2018-11-21 | 2023-01-04 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| MX2021006421A (es) | 2018-12-19 | 2021-08-16 | Leo Pharma As | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). |
| US12509453B2 (en) | 2019-01-29 | 2025-12-30 | Foghorn Therapeutics Inc. | BRM/BRG1 inhibitors and uses thereof |
| AU2020214308A1 (en) * | 2019-01-29 | 2021-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| JP2022525149A (ja) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置 |
| CA3150354A1 (en) | 2019-09-12 | 2021-03-18 | Muralidhara Ramachandra | METHOD FOR IDENTIFYING RESPONDERS TO SMARCA2/4 DEGRADATION AGENTS |
| WO2021081032A1 (en) | 2019-10-25 | 2021-04-29 | Dana-Farber Cancer Institute, Inc. | Compositions comprising modified smarcb1 and uses thereof |
| EA202192101A1 (ru) | 2019-11-21 | 2021-12-09 | Фогхорн Терапьютикс Инк. | Соединения и их применение |
| WO2021155262A1 (en) | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| BR112022015110A2 (pt) | 2020-01-29 | 2022-11-08 | Foghorn Therapeutics Inc | Compostos e usos dos mesmos |
| IL295176A (en) | 2020-01-29 | 2022-09-01 | Foghorn Therapeutics Inc | compounds and their uses |
| WO2021155264A1 (en) | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| BR112022015109A2 (pt) | 2020-01-29 | 2022-11-08 | Foghorn Therapeutics Inc | Compostos e usos dos mesmos |
| MX2022009308A (es) | 2020-01-29 | 2022-08-22 | Foghorn Therapeutics Inc | Compuestos y usos de estos. |
| US20250283871A1 (en) | 2020-03-13 | 2025-09-11 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating the interaction between ss18-ssx fusion oncoprotein and nucleosomes |
| WO2021236080A1 (en) | 2020-05-20 | 2021-11-25 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| US12606553B2 (en) | 2021-03-09 | 2026-04-21 | Foghorn Therapeutics Inc. | Crystalline forms, compositions containing same, and methods of their use |
| WO2022192621A1 (en) | 2021-03-12 | 2022-09-15 | Celgene Corporation | Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles |
| WO2022198043A1 (en) | 2021-03-19 | 2022-09-22 | Foghorn Therapeutics Inc. | Therapeutic regimens of an inhibitor of the enzymatic activity of brg1 and brm |
| US20240374605A1 (en) | 2021-07-29 | 2024-11-14 | Foghorn Therapeutics Inc. | Methods of treating cancer |
| US20250339441A1 (en) | 2022-04-08 | 2025-11-06 | Foghorn Therapeutics Inc. | Methods of treating cancer |
| WO2023196560A1 (en) | 2022-04-08 | 2023-10-12 | Foghorn Therapeutics Inc. | Methods of treating cancer |
| WO2023196567A2 (en) | 2022-04-08 | 2023-10-12 | Foghorn Therapeutics Inc. | Methods of treating a subject having clinically significant signs and symptoms associated with blood cell differentiation |
| CN218451564U (zh) | 2022-08-09 | 2023-02-07 | 宁波立奇电器有限公司 | 一种双锅双风道式空气炸锅 |
| WO2024086577A1 (en) | 2022-10-17 | 2024-04-25 | Foghorn Therapeutics Inc. | Methods of reducing or preventing metastases |
| WO2024216151A1 (en) | 2023-04-13 | 2024-10-17 | Foghorn Therapeutics Inc. | Combination therapy for treating hematological cancers |
| WO2024216136A1 (en) | 2023-04-13 | 2024-10-17 | Foghorn Therapeutics Inc. | Combination therapy for the treatment of hematological cancers |
| WO2024249769A2 (en) | 2023-06-02 | 2024-12-05 | Foghorn Therapeutics Inc. | Combination therapy for treating hematological cancers |
| WO2025080769A1 (en) | 2023-10-10 | 2025-04-17 | Foghorn Therapeutics Inc. | Methods of treating cancer |
| WO2025080767A1 (en) | 2023-10-10 | 2025-04-17 | Foghorn Therapeutics Inc. | Differentiation and maintenance dosing regimen for fhd 286 (brg1/brm inhibitor) |
-
2021
- 2021-01-29 WO PCT/US2021/015876 patent/WO2021155262A1/en not_active Ceased
- 2021-01-29 TW TW110103457A patent/TWI859406B/zh active
- 2021-01-29 PH PH1/2022/551937A patent/PH12022551937A1/en unknown
- 2021-01-29 EP EP21747908.8A patent/EP4096664B1/en active Active
- 2021-01-29 KR KR1020227029525A patent/KR20220133258A/ko active Pending
- 2021-01-29 BR BR112022015004A patent/BR112022015004A2/pt unknown
- 2021-01-29 JP JP2022546069A patent/JP7561195B2/ja active Active
- 2021-01-29 CA CA3167275A patent/CA3167275A1/en active Pending
- 2021-01-29 CN CN202180011631.1A patent/CN115023226A/zh active Pending
- 2021-01-29 AU AU2021213811A patent/AU2021213811A1/en active Pending
- 2021-01-29 US US17/162,103 patent/US11485732B2/en active Active
- 2021-01-29 UA UAA202202338A patent/UA129728C2/uk unknown
- 2021-01-29 AR ARP210100245A patent/AR121226A1/es unknown
- 2021-01-29 IL IL295100A patent/IL295100A/en unknown
- 2021-01-29 MX MX2022009309A patent/MX2022009309A/es unknown
-
2022
- 2022-07-13 ZA ZA2022/07804A patent/ZA202207804B/en unknown
- 2022-07-27 CO CONC2022/0010547A patent/CO2022010547A2/es unknown
- 2022-10-11 US US17/963,576 patent/US20230129003A1/en not_active Abandoned
-
2023
- 2023-09-27 US US18/373,518 patent/US12486262B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PH12022551937A1 (en) | 2023-10-23 |
| US11485732B2 (en) | 2022-11-01 |
| BR112022015004A2 (pt) | 2022-09-20 |
| AR121226A1 (es) | 2022-04-27 |
| CO2022010547A2 (es) | 2022-09-09 |
| TW202136252A (zh) | 2021-10-01 |
| AU2021213811A1 (en) | 2022-07-28 |
| MX2022009309A (es) | 2022-08-22 |
| JP2023512039A (ja) | 2023-03-23 |
| TWI859406B (zh) | 2024-10-21 |
| IL295100A (en) | 2022-09-01 |
| JP7561195B2 (ja) | 2024-10-03 |
| CN115023226A (zh) | 2022-09-06 |
| UA129728C2 (uk) | 2025-07-16 |
| ZA202207804B (en) | 2023-12-20 |
| CA3167275A1 (en) | 2021-08-05 |
| EP4096664A4 (en) | 2024-02-28 |
| US12486262B2 (en) | 2025-12-02 |
| US20230129003A1 (en) | 2023-04-27 |
| WO2021155262A1 (en) | 2021-08-05 |
| US20240101550A1 (en) | 2024-03-28 |
| US20210230154A1 (en) | 2021-07-29 |
| EP4096664B1 (en) | 2026-07-29 |
| EP4096664A1 (en) | 2022-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7561195B2 (ja) | 化合物及びその使用 | |
| US12509453B2 (en) | BRM/BRG1 inhibitors and uses thereof | |
| EP4244213A1 (en) | Compounds and uses thereof | |
| US20230121497A1 (en) | Compounds and uses thereof | |
| US20240374605A1 (en) | Methods of treating cancer | |
| EP4132529A1 (en) | Compounds and uses thereof | |
| WO2023220219A1 (en) | Compounds and uses thereof | |
| CA3254823A1 (en) | HETEROCYCLIC COMPOUNDS USEFUL FOR MODULATING BAF COMPLEXES | |
| US12528825B2 (en) | Compounds and uses thereof | |
| AU2023269999A1 (en) | Benzoyparazine pyrazines ane their uses | |
| EP4337211A1 (en) | Compounds and uses thereof | |
| EA047636B1 (ru) | Соединения и способы их применения | |
| HK40080608A (en) | Compounds and uses thereof | |
| OA21277A (en) | Compounds and uses thereof. | |
| EP4709726A1 (en) | Compounds and uses thereof | |
| EP4522277A1 (en) | Pyrazine derivatives and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |